title: [Therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia].
abstract: OBJECTIVE
  To evaluate the therapeutic effect of harnal and proscar in treating benign prostatic hyperplasia (BPH).
  
  
  METHODS
  Two hundreds and twenty-two patients with BPH were randomly assigned into 2 groups:harnal (0.2 mg/d) group (n = 112) and proscar (5 mg/d) group (n = 108). American Urologic Association Symptom Index (AUA-SI) scores, the maximal urinary flow rate (Qmax) and prostatic volume were analyzed in the 2 groups.
  
  
  RESULTS
  After 12 weeks of treatment, 54.5% of the harnal group improved in AUA-SI score; 54.6% of the proscar group improved in AUA-SI score; and there was no significant difference between the 2 groups (P > 0.05). After 24 weeks of treatment, the proscar group (79.6%) had a greater improvement in AUA-SI score than the harnal group (64.3%) (P < 0.05); Qmax in the 2 groups was significantly increased than that before the treatment, and it is proportional to the therapeutic time. The prostatic volume in 2 groups had no significant change.
  
  
  CONCLUSIONS
  Harnal and proscar can significantly improve BPH symptoms and the urinary flow rate. The therapeutic effect of harnal and proscar has their own characteristics.
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China. xytzyan@163.com
authors.forename: Zheng-yan
authors.initials: ZY
authors.lastname: Tang
authors.forename: Ke-liang
authors.initials: KL
authors.lastname: Peng
authors.forename: Jian
authors.initials: J
authors.lastname: Ding
authors.forename: Xiong-bing
authors.initials: XB
authors.lastname: Zu
authors.forename: Lin
authors.initials: L
authors.lastname: Qi
mesh_terms: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D018120:Finasteride / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy*; D014555:Urination Disorders / Q000209:etiology / Q000503:physiopathology*; D014563:Urodynamics
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D018120:Finasteride